TRPV4 receptor ligands

A compound of formula (I),

• or a pharmaceutically acceptable salt thereof, wherein:
• L1 is —C(O)—, —S(O2)—, or —S(O)—;
• X is O or NR1;
• m is 1, 2, 3, or 4;
• n is 0;
• Ar1 and Ar2 are each independently selected from a 6-10 membered aryl or a 5-10 membered heteroaryl;
• Z is CHR2R3, COR4, or NHR5;
• R1 is selected from hydrogen and C1-C4alkyl;
• R2, R3, R4, and R5 are each independently selected from the group consisting of hydrogen, hydroxy, C1-C6alkyl, hydroxy-C1-C6alkyl, C1-C6alkoxy, C1-C6alkoxy-C1-C6alkyl, phosphate, C1-C6alkyl phosphate, C4-C8heterocyclyl, NR6R7, —OC(O)R8, —C(O)R9, —S(O)2R10, and —OS(O)2R11;
• R6, R7, R8, R9, R10, and R11 are each independently selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6heteroalkyl, C1-C6alkoxy, C4-C8cycloalkyl, C4-C8heterocyclyl, C6-C8aryl, C5-C8-heteroaryl, C1-C6alkoxy-C1-C6alkyl, C6-C8aryl-C1-C6alkyl, C5-C8heteroaryl-C1-C6alkyl, C5-C8heterocyclyl-C1-C6alkyl, amino-C1-C6alkyl, hydroxy-C1-C6alkyl, hydroxy-C3-C8cycloalkyl, cyano-C1-C6alkyl, hydroxysulfonyl-C1-C6alkyl, phosphate-C1-C6alkyl, alkylphosphate-C1-C6alkyl, —COR12, and —CR13R14C(O)R15;
• R12 is selected from the group consisting of C1-C6alkyl, C1-C6heteroalkyl, C1-C6alkoxy, amino-C1-C6alkyl, C4-C8heterocyclyl, hydroxy-C1-C6alkyl, amino-C4-C8heterocyclyl, phosphate-C1-C6alkyl, and C1-C6alkyl phosphate;
• R13 and R14 are each independently selected from the group consisting of hydrogen, C1-C6alkyl and, C1-C6heteroalkyl, or optionally taken together with the atoms to which they are attached to form a ring;
• and
• R15 is hydroxy, C1-C6alkoxy or amino;
• wherein each aryl, heteroaryl, cycloalkyl, or heterocycle is independently unsubstituted or substituted with one or more substituents independently selected from cyano, halo, C1-C6alkyl, C1-C6alkoxy, amino-C1-C6alkyl, haloalkyl, sulfonyl, —C(O)—C1-C6alkoxy, and —C(O)—NH2.